Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events

Item 8.01Other Events

As previously disclosed in a Current Report on Form 8-K filed on
December 19, 2016, Interpace Diagnostics Group, Inc. (the
Company) announced a registered direct public offering of
2,000,000 shares of the Companys common stock, par value $0.01
per share (the Common Stock), at a price of $0.53 per share and
prefunded warrants to purchase 1,600,000 shares of Common Stock
(the Registered Direct Offering). A copy of the legal opinion of
Pepper Hamilton LLP relating to the legality of the issuance and
sale of the shares of Common Stock, warrants and shares of Common
Stock issuable upon exercise of the warrants in the Registered
Direct Offering is filed herewith as Exhibit 5.1.

The closing of the Registered Direct Offering is expected to take
place on December 22, 2016, subject to customary closing
conditions.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking
statements. Forward-looking statements include, but are not
limited to, statements that express the Companys
intentions, beliefs, expectations, strategies, predictions or
any other statements related to the Companys
future activities, or future events or conditions. These
statements are based on current expectations, estimates and
projections about the Companys business based,
in part, on assumptions made by management. These statements are
not guarantees of future performances and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including those risks discussed in
the Companys Annual Report on Form 10-K and in other
documents that the Company files
from time to time with the U.S. Securities and
Exchange Commission. Any forward-looking statements
speak only as of the date on which they are made, and
the Company does not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of this report, except as
required by law.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group (NASDAQ:IDXG) closed its last trading session down -0.067 at 0.721 with 1,434,494 shares trading hands.